The National Pharmaceutical Pricing Authority has revised prices of 40-odd drugs including some eye drops, paracetamol oralliquids, HIV drugs, cancer drug, non-steroidal fertility medicines, Asthma drugs,drugs to cure tuberculosis. With this inclusion, the NPPA has brought 540 drugs under price control from 10 th of March 2016. According to latest estimates by ICRA, approximately 17% of the Indian pharmaceuticalmarketis under the DPCO. The DPCO segment has grown by 1.1% during the first quarter of 2016-17. ICRA expects the DPCO segment to grow at 1-3% in 2016-17 while the overall market will grow at 10-12%.
The NPPA had fixed and revised 31 scheduled formulations in October this year. The National Pharmaceutical Pricing Authority is an independent regulator of prices in the pharmaceutical sector. The organisation fixes and monitors prices of drugs that are part of the National List of Essential Medicine.